BUSINESS

Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success

April 16, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Chugai Pharmaceutical’s bispecific antibody Vabysmo (faricimab) is heading towards a regulatory filing in Japan next year for a label expansion into angioid streaks now that the drug has hit the main goal in a relevant domestic study. The Roche group…

To read the full story

Vabysmo Filed for Label Expansion into Angioid Streaks in Japan: Chugai
September 9, 2024

BUSINESS

Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
Ono’s Velexbru Accepted for FDA Review in PCNSL
February 17, 2026
Celltrion Sets April 28 Launch Date for Japan’s 1st Actemra Biosimilar
February 17, 2026
Nxera Cuts Executive Pay as Losses Widen
February 16, 2026
Otsuka Pharma Sales Rise 7.1% in 2025, Driven by Rexulti
February 16, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…